R Alex Harbison1,2,3, Mark Kubik4, Eric Q Konnick5, Qing Zhang6, Seok-Geun Lee3,7, Heuijoon Park3, Jianan Zhang8, Christopher S Carlson9, Chu Chen1,2,9, Stephen M Schwartz2,9, Cristina P Rodriguez3,10, Umamaheswar Duvvuri4, Eduardo Méndez1,3. 1. Departments of Otolaryngology, University of Washington School of Medicine, Seattle, Washington, USA. 2. Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, USA. 3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 4. Veterans Affairs Pittsburgh Health System, Pittsburgh PA. 5. Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington, USA. 6. Genomics & Bioinformatics Shared Resources, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 7. Department of Science in Korean Medicine, Kyung Hee University, Seoul, South Korea. 8. Solid Tumor Translational Research/Human Biology and. 9. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 10. Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Abstract
BACKGROUND: Human papillomavirus-related (HPV-related) oropharyngeal squamous cell carcinomas (OPSCCs) have an excellent response rate to platinum-based chemoradiotherapy. Genomic differences between primary HPV-related OPSCCs that do or do not recur are unknown. Furthermore, it is unclear if HPV-related OPSCCs that recur share a genomic landscape with HPV-negative head and neck cancers (HNCs). METHODS: We utilized whole exome sequencing to analyze somatic nucleotide (SNVs) and copy number variants (CNVs) among a unique set of 51 primary HPV-related OPSCCs, including 35 that did not recur and 16 that recurred. We evaluated 12 metachronous recurrent OPSCCs (7 with paired primary OPSCCs) and 33 primary HPV-unrelated oral cavity and OPSCCs. RESULTS: KMT2D was the most frequently mutated gene among primary HPV-related OPSCCs (n = 51; 14%) and among metachronous recurrent OPSCCs (n = 12; 42%). Primary HPV-related OPSCCs that recurred shared a genomic landscape with primary HPV-related OPSCCs that did not recur. However, TSC2, BRIP1, NBN, and NFE2L2 mutations occurred in primary OPSCCs that recurred but not in those that did not recur. Moreover, primary HPV-related OPSCCs that recur harbor features of HPV-unrelated HNCs, notably including MAPK, JAK/STAT, and differentiation signaling pathway aberrations. Metachronous recurrent OPSCCs shared a genomic landscape with HPV-unrelated HNCs, including a high frequency of TP53, CASP8, FAT1, HLA-A, AJUBA, and NSD1 genomic alterations. CONCLUSION: Overall, primary HPV-related OPSCCs that recur share a genomic landscape with nonrecurrent OPSCCs. Metachronous recurrent OPSCCs share genomic features with HPV-negative HNCs. These data aim to guide future deescalation endeavors and functional experiments. FUNDING: This study is supported by the American Cancer Society (RSG TBG-123653), funding support for RAH (T32DC00018, Research Training in Otolaryngology, University of Washington), funds to EM from Seattle Translational Tumor Research (Fred Hutchinson Cancer Research Center), and center funds from the Fred Hutchinson Cancer Research Center to EM. UD is supported by the Department of Veterans Affairs, Biomedical Laboratory Research and Development (BLR&D), grant IO1-oo23456, and funds from the Pittsburgh Foundation and PNC Foundation.
BACKGROUND:Human papillomavirus-related (HPV-related) oropharyngeal squamous cell carcinomas (OPSCCs) have an excellent response rate to platinum-based chemoradiotherapy. Genomic differences between primary HPV-related OPSCCs that do or do not recur are unknown. Furthermore, it is unclear if HPV-related OPSCCs that recur share a genomic landscape with HPV-negative head and neck cancers (HNCs). METHODS: We utilized whole exome sequencing to analyze somatic nucleotide (SNVs) and copy number variants (CNVs) among a unique set of 51 primary HPV-related OPSCCs, including 35 that did not recur and 16 that recurred. We evaluated 12 metachronous recurrent OPSCCs (7 with paired primary OPSCCs) and 33 primary HPV-unrelated oral cavity and OPSCCs. RESULTS:KMT2D was the most frequently mutated gene among primary HPV-related OPSCCs (n = 51; 14%) and among metachronous recurrent OPSCCs (n = 12; 42%). Primary HPV-related OPSCCs that recurred shared a genomic landscape with primary HPV-related OPSCCs that did not recur. However, TSC2, BRIP1, NBN, and NFE2L2 mutations occurred in primary OPSCCs that recurred but not in those that did not recur. Moreover, primary HPV-related OPSCCs that recur harbor features of HPV-unrelated HNCs, notably including MAPK, JAK/STAT, and differentiation signaling pathway aberrations. Metachronous recurrent OPSCCs shared a genomic landscape with HPV-unrelated HNCs, including a high frequency of TP53, CASP8, FAT1, HLA-A, AJUBA, and NSD1 genomic alterations. CONCLUSION: Overall, primary HPV-related OPSCCs that recur share a genomic landscape with nonrecurrent OPSCCs. Metachronous recurrent OPSCCs share genomic features with HPV-negative HNCs. These data aim to guide future deescalation endeavors and functional experiments. FUNDING: This study is supported by the American Cancer Society (RSG TBG-123653), funding support for RAH (T32DC00018, Research Training in Otolaryngology, University of Washington), funds to EM from Seattle Translational Tumor Research (Fred Hutchinson Cancer Research Center), and center funds from the Fred Hutchinson Cancer Research Center to EM. UD is supported by the Department of Veterans Affairs, Biomedical Laboratory Research and Development (BLR&D), grant IO1-oo23456, and funds from the Pittsburgh Foundation and PNC Foundation.
Entities:
Keywords:
Cancer; Head & neck cancer; Molecular diagnosis; Oncology
Authors: Carole Fakhry; Qiang Zhang; Phuc Felix Nguyen-Tan; David Rosenthal; Adel El-Naggar; Adam S Garden; Denis Soulieres; Andy Trotti; Vilija Avizonis; John Andrew Ridge; Jonathan Harris; Quynh-Thu Le; Maura Gillison Journal: J Clin Oncol Date: 2014-06-23 Impact factor: 44.544
Authors: George L Sen; Lisa D Boxer; Dan E Webster; Rose T Bussat; Kun Qu; Brian J Zarnegar; Danielle Johnston; Zurab Siprashvili; Paul A Khavari Journal: Dev Cell Date: 2012-02-23 Impact factor: 12.270
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis Journal: Cancer Discov Date: 2013-04-25 Impact factor: 39.397
Authors: Hannah Carter; Christopher Douville; Peter D Stenson; David N Cooper; Rachel Karchin Journal: BMC Genomics Date: 2013-05-28 Impact factor: 3.969
Authors: Eliezer M Van Allen; Nikhil Wagle; Petar Stojanov; Danielle L Perrin; Kristian Cibulskis; Sara Marlow; Judit Jane-Valbuena; Dennis C Friedrich; Gregory Kryukov; Scott L Carter; Aaron McKenna; Andrey Sivachenko; Mara Rosenberg; Adam Kiezun; Douglas Voet; Michael Lawrence; Lee T Lichtenstein; Jeff G Gentry; Franklin W Huang; Jennifer Fostel; Deborah Farlow; David Barbie; Leena Gandhi; Eric S Lander; Stacy W Gray; Steven Joffe; Pasi Janne; Judy Garber; Laura MacConaill; Neal Lindeman; Barrett Rollins; Philip Kantoff; Sheila A Fisher; Stacey Gabriel; Gad Getz; Levi A Garraway Journal: Nat Med Date: 2014-05-18 Impact factor: 53.440
Authors: Avani Vyas; R Alex Harbison; Daniel L Faden; Mark Kubik; Drake Palmer; Qing Zhang; Hatice U Osmanbeyoglu; Kirill Kiselyov; Eduardo Méndez; Umamaheswar Duvvuri Journal: Clin Cancer Res Date: 2021-08-18 Impact factor: 12.531
Authors: Robert M Brody; David Shimunov; Roger B Cohen; Alexander Lin; John N Lukens; Lee Hartner; Charu Aggarwal; Umamaheswar Duvvuri; Kathleen T Montone; Jalal B Jalaly; Virginia A LiVolsi; Ryan M Carey; Rabie M Shanti; Karthik Rajasekaran; Ara A Chalian; Christopher H Rassekh; Steven B Cannady; Jason G Newman; Bert W O'Malley; Gregory S Weinstein; Phyllis A Gimotty; Devraj Basu Journal: Oral Oncol Date: 2022-03-01 Impact factor: 5.972
Authors: Robert L Ferris; William C Spanos; Rom Leidner; Anthony Gonçalves; Uwe M Martens; Chrisann Kyi; William Sharfman; Christine H Chung; Lot A Devriese; Helene Gauthier; Simon I Chiosea; Lazar Vujanovic; Janis M Taube; Julie E Stein; Jun Li; Bin Li; Tian Chen; Adam Barrows; Suzanne L Topalian Journal: J Immunother Cancer Date: 2021-06 Impact factor: 12.469
Authors: Nicole D Facompre; Pavithra Rajagopalan; Varun Sahu; Alexander T Pearson; Kathleen T Montone; Claire D James; Frederico O Gleber-Netto; Gregory S Weinstein; Jalal Jalaly; Alexander Lin; Anil K Rustgi; Hiroshi Nakagawa; Joseph A Califano; Curtis R Pickering; Elizabeth A White; Bradford E Windle; Iain M Morgan; Roger B Cohen; Phyllis A Gimotty; Devraj Basu Journal: Int J Cancer Date: 2020-07-06 Impact factor: 7.396
Authors: Henrike Reder; Steffen Wagner; Nora Wuerdemann; Christine Langer; Sarah Sandmann; Andreas Braeuninger; Martin Dugas; Stefan Gattenloehner; Claus Wittekindt; Jens Peter Klussmann Journal: Cancer Med Date: 2021-02-01 Impact factor: 4.452
Authors: Vlad C Sandulache; David C Wilde; Erich M Sturgis; Elizabeth Y Chiao; Andrew G Sikora Journal: Laryngoscope Investig Otolaryngol Date: 2019-10-17
Authors: Erik A Williams; Adrienne J Werth; Radwa Sharaf; Meagan Montesion; Ethan S Sokol; Dean C Pavlick; Molly McLaughlin-Drubin; Rachel Erlich; Helen Toma; Kevin Jon Williams; Jeff M Venstrom; Brian M Alexander; Nikunj Shah; Natalie Danziger; Amanda C Hemmerich; Eric A Severson; Jonathan Keith Killian; Douglas I Lin; Jeffrey S Ross; Julie Y Tse; Shakti H Ramkissoon; Mark C Mochel; Julia A Elvin Journal: JCO Precis Oncol Date: 2020-06-16